In the News
Novel strategy of attacking sugars on cancer cells to free immune system shows promise in early tests
STAT
Palleon unveils PhI look at ‘lawn mower’ approach to glycoimmunology: #AACR23
Endpoints
What A Nobel Prize-Winner’s Research Means for Cancer Treatment
MedCity News
Stanford’s Carolyn Bertozzi, 2022 Nobel Laureate in Chemistry, on translational science
Stanford School of Humanities and Sciences
Stanford’s Carolyn Bertozzi wins Nobel Prize in chemistry
Stanford
With details on lead sialoglycan degrader in place, Palleon raises $100M series B
BioCentury
Palleon battalion bags $100M series B for glycan push
BioWorld
Palleon Pharmaceuticals secures $100m in Series B funding
Pharmaceutical Technology
Jim Broderick reels in a $100M Series B to explore a ‘new and big’ angle of immune regulation
Endpoints
Palleon’s first CSO explains how they (and she) got here; Enterprise taps Roche and Novartis vet David Morris as CMO
Endpoints
Beyond PROTACs and the proteasome: broadening the TAC toolbox
BioCentury
Carolyn Bertozzi’s glycorevolution
Chemical & Engineering News
SIGLECs go from homing beacons to next-generation checkpoints
BioCentury
Glycoscience fuels a new breed of cancer immunotherapy
Chemical & Engineering News
Carolyn Bertozzi on becoming a chemical biologist/glycobiologist
The Long Run with Luke Timmerman
Palleon: Sweeter checkpoints
BioCentury
The Biology of Sugars Points to a Sweet Strategy for Treating Cancer
Scientific American
Startup Palleon has a sweet plan for cancer immunotherapy
FierceBiotech
Cancer cells cast a sweet spell on the immune system
ScienceNews